Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
14,296 people get ABT articles and Market Currents by email alert.
Get email alerts on ABT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30 -
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Abbott Hopes Mitral Repair Will Be The New TAVIEP Vantage • Wed, Feb 27 -
-
-
-
-
-
-
-
Abbott Earnings Preview: What We Are WatchingTrefis • Tue, Jan 22
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30
-
-
-
-
-
-
-
-
-
-
Abbott Laboratories' Management Presents HCV Program Update (Transcript)Mon, Nov 12, 2012
-
Abbott Laboratories Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Abbott Laboratories Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
Abbott Laboratories, Q3 2009 Earnings Call TranscriptWed, Oct 14, 2009
-
Abbott Laboratories, Q2 2009 Earnings Call TranscriptWed, Jul 15, 2009 • 1 Comment
-
Abbott Laboratories Q1 2009 Earnings Call TranscriptFri, Apr 17, 2009
-
Abbott Laboratories Q4 2008 Earnings Call TranscriptWed, Jan 21, 2009
-
at CNBC.com (Fri, 6:29PM)
-
at CNBC.com (Fri, 6:02PM)
-
at CNBC.com (May 13, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
at CNBC.com (Mar 20, 2013)
-
at CNBC.com (Mar 11, 2013)
-
at CNBC.com (Feb 14, 2013)
-
at MarketWatch.com (Jan 30, 2013)
-
at MarketWatch.com (Jan 23, 2013)
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable revenue segments: Pharmaceutical Products, Diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, December 21, 2009, 6:03 PM Morningstar looks back over some of their most frequently discussed stock picks to plumb them for price-to-value ideas for 2010: heavy on healthcare, including Genzyme (GENZ), Stryker (SYK) and Abbott Labs (ABT). 1 Comment
- Monday, December 14, 2009, 4:49 PM Abbott Labs (ABT) shores up its position in the diagnostics market by agreeing to acquiring STARLIMS Technologies (LIMS) for $123M in cash; ABT -0.2% AH. (PR) Comment!
- Monday, November 16, 2009, 7:51 AM A new trial found a reduction in the thickness of artery walls in patients given Abbott Laboratories' (ABT) Niaspan, while those on Merck's (MRK) Zetia had no change. The results, reported yesterday at a American Heart Association meeting, could pump up sales for Abbott’s drug, though some doctors have questioned the validity of the study. Comment!
- Sunday, October 18, 2009, 2:55 AM Pfizer's (PFE) experimental oral rheumatoid arthritis drug was effective both as a standalone and in combination with standard treatments, a final analysis of data from mid-stage studies shows. "People should be extremely excited about it," lead researcher Dr. Roy Fleischmann says, noting it should be cheaper than current biotech solutions like Abbott's (ABT) Humira and Amgen's (AMGN) Enbrel. Comment!
- Wednesday, October 14, 2009, 7:59 AM Abbott Laboratories (ABT): Q3 EPS of $0.92 beats by $0.02. Revenue of $7.76B (+3.5%) in-line. Shares +3% premarket. (PR) Comment!
- Wednesday, October 14, 2009, 12:05 AM Notable pre-market earnings: ABT, ASML, HST, JPM, LPL Comment!
- Tuesday, September 29, 2009, 5:55 PM With markets up almost 50% since March, fund managers are generally treading carefully. Here are some stocks the group says may still have some juice: Commodities (RIG, STLD), healthcare (ABT, GILD), business spending (AMD, ASML), and top fliers that were left behind (BMY, VZ, WMT). 1 Comment
- Sunday, September 27, 2009, 9:48 AM Abbott (ABT) is close to announcing a deal to buy Belgian conglomerate Solvay's (SVYSY.PK) drug unit for about $7.6B in cash. A deal could be announced as early as Monday. Abbott and Solvay already sell two drugs for cholesterol and triglycerides together; a deal would give Abbott access to Solvay's drugs for hypertension and Parkinson's disease. (WSJ) Comment!
- Wednesday, September 2, 2009, 4:29 PM Abbott Laboratories (ABT) agrees to buy Visiogen - maker of eye-implanted lenses for cataract patients - for $400M in cash. Comment!
- Thursday, August 27, 2009, 10:52 AM Abbott Laboratories (ABT +0.1%) and Pfizer (PFE -0.3%) say they'll join forces to develop a test to screen lung cancer patients to determine which are good candidates for a novel cancer therapy being developed by Pfizer. The test will look for cells that have incurred gene rearrangement, or translocation. Comment!
- Thursday, August 27, 2009, 9:57 AM Abbott Laboratories (ABT +0.1%) and Pfizer (PFE -0.7%) say they'll join forces to develop a test to screen lung cancer patients to determine which are good candidates for a novel cancer therapy being developed by Pfizer. The test will look for cells that have incurred gene rearrangement, or translocation. Comment!
- Monday, July 27, 2009, 8:50 AM Medtronic (MDT) settles all outstanding intellectual-property litigation with Abbott Laboratories (ABT), agreeing to pay $400M and $42M to evYsio Medical Devices. MDT +1% premarket; ABT +0.4%. Comment!
- Wednesday, July 15, 2009, 7:57 AM Abbott Laboratories (ABT): Q2 EPS of $0.89 in-line. Revenue of $7.5B (+2.5%) in-line. Shares -0.4% premarket. (PR) Comment!
- Wednesday, July 15, 2009, 12:05 AM Notable earnings before Wednesday's open: ABT, ASML, GCI, GWW Comment!
- Tuesday, June 30, 2009, 12:15 PM FDA panel votes to lower the maximum dose of Tylenol (JNJ -0.8%) and its generic imitations over concerns of liver damage. J&J opened higher after winning a $1.67B verdict against Abbott (ABT -2.8%), but dropped in a hurry. Comment!
- Tuesday, June 30, 2009, 7:24 AM Abbott Laboratories (ABT) is ordered to pay $1.67B in a patent suit brought by Johnson & Johnson (JNJ). J&J had alleged Abbott's Humira arthritis therapy infringed on a patent for J&J's rival treatment Remicade. Abbott plans to appeal the ruling. Comment!
-
- View all 3 replies
-
-
-
- View all 4 replies
-
-
-
- View all 3 replies
-
-
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 6 replies
-
Clayton Rulli: i was gonna pinch some at 76 a few days back but got greedy and missed the boat! -
-
- View all 2 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES